To our knowledge, this is the first trial of a pharmacologic agent to specifically target obesity as a treatment strategy for HFpEF, and the magnitude of the benefits we observed is the largest seen with any agent in HFpEF, he added
Semaglutide# Semaglutide alone activates GLP-1 receptors, producing appetite suppression, delayed gastric emptying, and improved glucose homeostasis
Consult your pharmacy for guidance if this happens
Practical counselling points The oral formulation introduces administration requirements that differ meaningfully from the injectable, and these should form a core part of counselling for anyone switching: The tablet must be taken on an empty stomach, first thing in the morning (minimum 8 hours of fasting), with no more than a small glass (up to 120ml) of plain water
To prevent drug buildup and reduce the risk of side effects, your healthcare provider may recommend beginning with a lower dose or raising the dose more gradually for older patients